87P - The comparative evaluation of radiotherapy with concurrent weekly cisplatin versus concurrent 3-weekly cisplatin and etoposide in patients with unre...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Puneet Bagri
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors P.K. Bagri1, P. Hirapara1, A. kapoor1, M. singhal1, D. singh1, S.L. jakhar1, S.K. Beniwal2, N. sharma1, H. kumar1, A. sharma1
  • 1Radiation Oncology, acharya tulsi regional cancer treatment and research institute, 334001 - bikaner/IN
  • 2Medical Oncology, Acharya Tulsi Cancer Treatment & Research Institut, 334001 - Bikaner/IN


In India, lung cancer is currently the fourth most common cancer and accounts for nearly 8% of all cancer related deaths. In our centre, lung cancer contributes approximately 8-10% of all newly diagnosed cases. This is a prospective comparison of weekly cisplatin to 3-weekly cisplatin and etoposide as concurrent chemotherapy with standard radiotherapy (CCRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).